Comprehensive genomic profiling and tumor mutational burden in parathyroid carcinoma: a nationwide real-world study from Japan.
Summary
This Japanese real-world study investigated comprehensive genomic profiling and tumor mutational burden (TMB) in parathyroid carcinoma, a rare endocrine malignancy. Among 25 patients, 28% exhibited elevated TMB (≥ 10 mut/Mb), with frequent alterations observed in CDC73, TP53, and MEN1 genes. POLE alterations and microsatellite instability (MSI-high) were also identified in some cases. These findings highlight the molecular heterogeneity of the disease and the value of genomic profiling for uncovering potential therapeutic opportunities.
Analysis
🔴 CLINIQUE: This retrospective real-world study, although based on a small cohort of 25 patients, underscores the importance of comprehensive genomic profiling for parathyroid carcinoma, a rare disease with limited treatment options. The detection of elevated TMB and specific genomic alterations could guide patients towards targeted therapies or enrollment in clinical trials, particularly for unresectable or recurrent cases. These findings suggest a potential clinical impact in the medium term (3-5 years) by justifying prospective studies and early-phase trials. 🟢 BIOMOL: The study discovered that a significant proportion (28%) of parathyroid carcinomas exhibit elevated TMB, a potential predictive biomarker for immunotherapy. The most frequently altered genes are CDC73, TP53, and MEN1, with POLE alterations and microsatellite instability (MSI-high) also noted, suggesting abnormalities in DNA replication or repair pathways. The technology employed was comprehensive genomic profiling (CGP), enabling broad analysis of genomic alterations. These discoveries have translational impact by identifying patient subgroups potentially eligible for specific treatments. 🔵 BIOINFO: The study utilized comprehensive genomic profiling data from a Japanese nationwide database (Center for Cancer Genomics and Advanced Therapeutics), representing a real-world application of these technologies. The definition of TMB-H (≥ 10 mut/Mb) is standardized, and TMB values were obtained from various CGP assays, which might introduce some analytical heterogeneity. The integration of such genomic data into a centralized database facilitates research on rare cancers and could eventually support clinical workflows for patient selection.